The Accelerated Access Collaborative will be hosting an online Town Hall event on Wednesday 15 December, 12-1pm, to discuss early learning from the implementation of inclisiran (Leqvio®) therapy as an option in the lipid management pathway in England via a Population Health Management approach.

Please save the date in your diary by registering for this free event. Registered attendees will receive the Teams event link ahead of the event date.

Implementing effective lipid management for patients is one of the national priorities for the NHS in England in the prevention and management of Cardiovascular Disease (CVD). Introducing innovation to the lipid pathway is one of the core components to enable this.

NICE published the Technology appraisal guidance [TA733] for inclisiran on 6 October 2021, recommending it as an option for use in the secondary prevention of ASCVD within the product licence and other reimbursement criteria (TA733 available here for full information on the recommendation)

The Agenda will include:

  • Initial findings from the ‘Study in primary care evaluating Inclisiran delivery implementation + enhanced support (VICTORION-SPIRIT)’
  • A panel discussion with AHSNs to share early learning on implementation
  • An audience Q&A

The full agenda with speakers will be confirmed ahead of the event.

For any questions, please contact:england.lipidsphm@nhs.net

This event is for local health system leaders in Integrated Care Systems (ICSs), Primary Care Networks (PCNs), and Academic Health Science Networks (AHSNs) as well as primary care health care professionals such as GPs, practice-based pharmacists and nurses, and CVD/lipid experts who will be leading on activity to improve lipid management for patients as part of this national priority.

This event is not intended for patients and members of the public and is relevant only for the above audience.

Disclaimer: NHS England and Improvement is working with Novartis Pharmaceuticals UK Ltd as part of a collaboration which includes resources in the form of funding, skills, expertise, project management and administrative support. Ownership of the agenda and content of this meeting is the responsibility of NHS England and Improvement, and Novartis has had no input into its development. Novartis has checked the associated materials against the relevant guidance or codes, as applicable.

Full prescribing information and adverse event reporting can be found here  

167788 November 2021

Questions about this event?

Name: Lipid Management in-box

Email: england.lipidsphm@nhs.net

Telephone: 07918 368472